Abstract:BACKGROUND: Oncogenic activation of PI3Kα via mutation of PIK3CA is the most common kinase driver event across solid tumors, particularly breast cancer (BC). Alpelisib, an orthosteric inhibitor, validated mutant-PI3Kα as a therapeutic target; however, toxicity from non-selective inhibition of WT PI3Kα (hyperglycemia) and other PI3K isoforms limits its clinical activity. RLY-2608, a novel oral allosteric PI3Kα inhibitor, is designed to overcome these limitations via mutant- and isoform-selective PI3Kα inhibition. We initiated a first-in-human study (NCT05216432) to define the MTD, safety, pharmacokinetics (PK), and anti-tumor activity of RLY-2608 in PIK3CA-mutant solid tumor patients (pts) and of RLY-2608 plus fulvestrant (combo) in pts with PIK3CA-mutant, HR+HER2-BC, who had received prior CDK4/6 inhibitor and endocrine therapy. METHODS: Adult pts with no prior PI3Ki/mTORi therapy received RLY-2608 QD or BID on a 4-week (wk) cycle following a Bayesian Optimal Interval dose escalation. Eligible BC pts received fulvestrant. PK, pharmacodynamics (ex vivo pAKT inhibition; tumor markers; ctDNAs), treatment emergent adverse events (TEAEs), and anti-tumor activity per RECIST 1.1 were assessed. RESULTS: As of 31Jan23, 40 pts (21 BC combo pts) with PIK3CA mutations (12 kinase, 18 helical, 10 other) received RLY-2608 at doses of 100-1600 mg/day. Median number of prior treatments was 4 (1-11). An MTD has not been reached and dose escalation continues. RLY-2608 PK were favorable with BID dosing providing low steady-state peak-to-trough variability for mutant-selective inhibition. This enabled dose-dependent increase in exposure and target inhibition with doses ≥600 mg BID and pAKT suppression (≥80%) in the expected therapeutic range with minimal/no impact on glucose homeostasis. Across arms, safety was consistent: most frequent TEAEs (>15%) were low grade (≤Gr 2) nausea (30%), fatigue (22.5%), headache (22.5%), hypokalemia (22.5%), and diarrhea (17.5%). No DLTs were observed, and no pts discontinued due to related AEs. Initial anti-tumor activity was observed in BC combo pts including declines in tumor markers, PIK3CA/ESR1 ctDNAs and radiographic tumor reduction in 7 of 10 RECIST measurable pts. At 600 mg BID, 6/6 BC combo pts had disease stabilization and remain on treatment, including all RECIST-measurable pts with tumor reduction. Overall, 17 (81%) BC combo pts remain on treatment with median duration of 12 (1-40) wks. CONCLUSION: Across PIK3CA genotypes, RLY-2608 demonstrated target inhibition and anti-tumor activity with minimal impact on glucose homeostasis. These proof-of-mechanism data indicate that RLY-2608 is the first allosteric, pan-mutant selective PI3Kα inhibitor and that RLY-2608 has broad therapeutic potential in PIK3CA-driven cancers. Citation Format: Andreas Varkaris, Komal Jhaveri, Cesar A. Perez, Janice S. Kim, Jason T. Henry, Vivek Subbiah, Alexander I. Spira, Lucía Sanz Gómez, Angel I. Guerrero-Zotano, Kari B. Wisinski, Xiaoyan Li, Gege Tan, Ramin Samadani, Tamieka Lauz Hunter, Wei Guo, Alison Timm, Djuro Karanovic, Beni B. Wolf, Erika P. Hamilton, Alison M. Schram. Pan-mutant and isoform selective PI3Kα inhibitor, RLY-2608, demonstrates selective targeting in a first-in-human study of PIK3CA-mutant solid tumor patients, ReDiscover trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT017.

Precision Targeting of Mutant PI3Kα

Development of small-molecule inhibitors that target PI3Kβ

Development of small-molecule inhibitors that target PI3K13

Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein

Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells

Advances in Subunits of PI3K Class I in Cancer.

PI3K Inhibitors for Cancer Therapy: What Has Been Achieved So Far?

Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer

Abstract 1954: Development of highly potent, covalent, and selective inhibitors to target PI3Kα in cancer

ATP-competitive inhibitors of PI3K enzymes demonstrate an isoform selective dual action by controlling membrane binding

Free energy landscape of the PI3Kα C-terminal activation

The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models

Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers

Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα

Novel inhibitors of the PI3K family

Targeting the PI3K pathway in cancer: are we making headway?

Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer

AKT kinases as therapeutic targets

Phosphoproteomics Identifies PI3K Inhibitor-selective Adaptive Responses in Pancreatic Cancer Cell Therapy and Resistance

Abstract CT017: Pan-mutant and Isoform Selective PI3Kα Inhibitor, RLY-2608, Demonstrates Selective Targeting in a First-in-human Study of PIK3CA-mutant Solid Tumor Patients, ReDiscover Trial